Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics (NASDAQ: IOVA) announced senior leadership will present at two upcoming investor conferences in March 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Iovance Biotherapeutics (NASDAQ: IOVA) announced senior leadership will present at two upcoming investor conferences in March 2026. Presentations: TD Cowen 46th Annual Healthcare Conference on March 2, 2026 at 9:50 a.m. ET and Barclays 28th Annual Global Healthcare Conference fireside chat on March 11, 2026 at 9:30 a.m. ET.
Live and archived webcasts will be available via the company investor events page at the provided webcast link.
Details
News Market Reaction – IOVA
On Feb 26, the day this news came out, IOVA closed 1.04% below the previous close.
Data tracked by StockTitan Argus for the Feb 26 session.
Key Figures
- TD Cowen presentation time
- March 2, 2026 at 9:50 a.m. ET
- TD Cowen 46th Annual Healthcare Conference
- Barclays fireside chat time
- March 11, 2026 at 9:30 a.m. ET
- Barclays 28th Annual Global Healthcare Conference
Historical Context
-
Positive early lifileucel data in UPS and DDLPS with 50% ORR.
-
Strong Q4 and 2025 revenue, improved gross margin, and cash runway into Q3 2027.
-
Small inducement stock option grants under Nasdaq Listing Rule 5635(c)(4).
-
Announcement of date and time for Q4 and full-year 2025 results call.
-
Real-world Amtagvi data showing 44% ORR and 73% disease control in melanoma.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
tumor infiltrating lymphocyte medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:
- TD Cowen 46th Annual Healthcare Conference
Presentation: March 2, 2026 at 9:50 a.m. ET
Boston, MA
- Barclays 28th Annual Global Healthcare Conference
Fireside Chat: March 11, 2026 at 9:30 a.m. ET
Miami, FL
The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi ® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.